Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7891 to 7905 of 8941 results

  1. Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528)

    This guidance has been updated and replaced by NICE technology appraisal guidance 784.

    Withdrawn guidance

  2. Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1021.

    Withdrawn guidance

  3. Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)

    This guidance has been updated and replaced by NICE technology appraisal guidance 766.

    Withdrawn guidance

  4. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (TA554)

    This guidance has been updated and replaced by NICE technology appraisal guidance 975.  

    Withdrawn guidance

  5. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA557)

    This guidance has been updated and replaced by NICE technology appraisal guidance 683.

    Withdrawn guidance

  6. Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA558)

    This guidance has been updated and replaced by NICE technology appraisal guidance 684.

    Withdrawn guidance

  7. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA559)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA872.

    Withdrawn guidance

  8. Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA578)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA798.

    Withdrawn guidance

  9. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA579)

    This guidance has been replaced by NICE's technology appraisal guidance on abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.

    Withdrawn guidance

  10. Flu treatment - zanamivir, amantadine and oseltamivir (TA58)

    This guidance has been updated and replaced by NICE technology appraisal guidance 168.

    Withdrawn guidance

  11. Cenegermin for treating neurotrophic keratitis (TA532)

    We have withdrawn the guidance because cenegermin (Oxervate) is no longer available in the UK.

    Withdrawn guidance

  12. Guidance on the use of vinorelbine for the treatment of advanced breast cancer (TA54)

    This guidance has been updated and replaced by NICE guideline CG81.

    Withdrawn guidance

  13. Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG641)

    This guidance has been updated and replaced by HealthTech guidance 639.

    Withdrawn guidance

  14. Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine (IPG559)

    This guidance has been updated and replaced by NICE HealthTech guidance 643.

    Withdrawn guidance

  15. Pneumonia (community-acquired): antimicrobial prescribing (NG138)

    This guideline has been updated and replaced by NICE's guideline on pneumonia in adults: diagnosis and management (NG250).

    Withdrawn guideline